Bacteriostatic non-menstrual-period protection pad based on sustained-release capsules and preparation method of bacteriostatic non-menstrual-period protection pad

Abstract

The invention relates to the field of hygienic products, in particular to a bacteriostatic non-menstrual-period panty liner based on a sustained-release capsule and a preparation method thereof.It is found through screening that matrine and lactein have the synergistic bacteriostatic effect, the bacteriostatic composition is prepared into a sustained-release microcapsule, long-acting sustained release of antibacterial components is achieved, and the antibacterial effect is good. The sustained-release capsule is prepared into the bacteriostatic non-menstrual period protection pad based on the sustained-release capsule. The air permeability and the moisture permeability of the protection pad are superior to those of the prior art, the comfort and the safety of non-menstrual female hygiene care are remarkably improved, and the protection pad is suitable for daily hygiene maintenance and infection prevention.

Description

Technical Field

[0001] The present invention relates to the field of sanitary products, and in particular to an antibacterial non-menstrual pad based on sustained-release capsules and a preparation method thereof. Background Art

[0002] Currently, non-menstrual pads on the market still have many technical deficiencies in meeting women's daily hygiene needs, mainly manifested in insufficient breathability, limited antibacterial properties, and poor comfort. Traditional pads typically use a basic three-layer structure: a surface layer of material that directly contacts the skin, a middle absorbent layer, and a bottom layer of anti-leakage membrane. This structural design exposes obvious problems with long-term use. The bottom layer material is mostly made of completely impermeable cast film, which causes the user's local skin temperature and humidity to increase significantly, creating a damp and stuffy feeling, especially in summer or high temperature environments. This humid and hot environment is extremely prone to bacterial growth, not only causing skin discomfort, but also potentially posing a risk of gynecological infections.

[0003] For non-menstrual users, the amount of non-menstrual secretions is small, and the existing water absorption layer design is redundant, with an absorption capacity of 10-15ml, which far exceeds the actual demand. In addition, the antibacterial performance of existing non-menstrual pads has the problem of insufficient antibacterial ability. Most commercially available pads rely solely on physical barriers and do not integrate effective antibacterial sustained-release systems, making it impossible to inhibit microbial growth in the long term. Although some products add antibacterial ingredients, most of them are released once and cannot achieve continuous protection. In addition, the structural design of traditional pads is relatively simple, lacking differentiated absorption and diversion mechanisms tailored to the characteristics of non-menstrual secretions, resulting in excessive local absorption capacity or uneven distribution. Therefore, it is of great significance to study new non-menstrual pads to solve the technical problems of existing pads such as insufficient breathability, lack of continuous antibacterial function, and structural redundancy when used during non-menstrual periods. Summary of the Invention

[0004] In order to solve the above technical problems, the present invention discovered matrine through screening, which has a synergistic effect with lactobacillus, and found through antibacterial tests that the combination of the two has good antibacterial efficacy against Candida albicans. The synergistic antibacterial composition was then prepared into a sustained-release microcapsule preparation, and an antibacterial non-menstrual pantyliner based on this technology was further developed.

[0005] In one aspect, the present invention provides an antibacterial composition, which consists of matrine and lactobacillus, and which inhibits the growth of Candida albicans.

[0006] Furthermore, in the antibacterial composition, the mass ratio of matrine to lactobacillus is 0.005-0.02:1-3.

[0007] In a second aspect, the present application further provides a sustained-release microcapsule comprising the bacteriostatic composition as a core component and having a double-layer structure formed by sodium alginate gel microspheres and chitosan coating.

[0008] Further, the sustained-release microcapsule is characterized in that the sodium alginate gel microspheres are formed by dropping the core component emulsion into a sodium alginate solution and solidified in the solution.

[0009] Further, in the sustained-release microcapsule, the chitosan coating is achieved by immersing the sodium alginate gel microspheres in a chitosan solution with a pH of 5.0.

[0010] Further, in the sustained-release microcapsule, the particle size of the sustained-release microcapsule is 150-200 μm, and the wall thickness is 10-15 μm.

[0011] In a third aspect, the present application further provides a bacteriostatic non-menstrual pad based on the sustained-release microcapsule, comprising:

[0012] a surface layer made of a silk protein modified non-woven fabric with a pore size of 80-120 μm and a pore rate of ≥ 35%;

[0013] a functional layer composed of a cellulose-based 3D network support, the functional layer loaded with the sustained-release microcapsule;

[0014] and a bottom layer.

[0015] Further, in the bacteriostatic non-menstrual pad, the loading density of the sustained-release microcapsule in the functional layer is 50-80 per cm 2 .

[0016] Finally, the present application further provides a preparation method of the bacteriostatic non-menstrual pad, comprising the following steps:

[0017] S1, immersing the cellulose-based network support in a sustained-release microcapsule suspension and fixing the microcapsule by vacuum adsorption;

[0018] S2, combining the surface layer and the functional layer by hot point welding at 80°C and 0.3 MPa for 2 seconds, and combining the functional layer and the bottom layer by room temperature adhesion of medical-grade polyurethane glue for 24 hours;

[0019] S3, cutting and sealing packaging.

[0020] Finally, the present application further provides a bacteriostatic non-menstrual pad prepared by the preparation method, the bacteriostatic non-menstrual pad having a bacteriostatic effect, and the bacteriostasis being inhibition of Candida albicans.

[0021] Compared with the prior art, the present application has at least the following advantages or beneficial effects: ​

[0022] The surface layer of the present invention adopts silk protein modified non-woven fabric with a pore size of 80-120μm and a porosity of ≥35%, combined with the breathable design of the bottom layer to achieve efficient air circulation, significantly reduce the temperature and humidity of the skin surface, avoid stuffiness, and reduce the risk of gynecological infections.

[0023] The present invention uses a synergistic antibacterial composition of matrine and lactobacillus, combined with sodium alginate-chitosan double-layer coated sustained-release microcapsule technology, to achieve the slow release of antibacterial ingredients, extend the antibacterial time, significantly enhance the inhibitory effect on pathogens such as Candida albicans, and the antibacterial effect is long-lasting and stable.

[0024] The functional layer of the present invention adopts a cellulose-based 3D mesh scaffold and loads sustained-release microcapsules to achieve uniform distribution of antibacterial ingredients. At the same time, through the surface perforated design and the three-dimensional structure of the functional layer, the secretion diversion and absorption efficiency are optimized, local excessive moisture is avoided, and the comfort of use is improved. DETAILED DESCRIPTION

[0025] The technical solutions of the present invention are described below with reference to the following embodiments; however, the present invention is not limited to the following embodiments.

[0026] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below with reference to specific embodiments, but the embodiments are not intended to limit the present invention.

[0027] The experimental methods and detection methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials are commercially available unless otherwise specified.

[0028] Lactobacillus, purity 99%, was purchased from Wuhan Rongcan Biotechnology Co., Ltd.

[0029] Matrine, purity 98%, was purchased from Shaanxi Sinuote Biotechnology Co., Ltd.

[0030] Example 1

[0031] This example is a test of the antibacterial effect of matrine and lactobacillus complex on Candida albicans.

[0032] According to the requirements of standard WS / T 650-2019 "Evaluation Methods for Antibacterial and Antibacterial Effects", the antibacterial properties of matrine and lactobacillus mixed and single agents were tested respectively.

[0033] Test strain: Candida albicans ATCC 10231

[0034] From the Candida albicans slant culture that had been cultured for 24 hours, the bacterial lawn was washed with phosphate buffered saline (PBS) and diluted to about 5×10 The bacterial suspension with a concentration of CFU / mL is ready for use.

[0035] The liquid of the test sample was weighed into a sterile dish at a rate of 5 g / tablet, and the infected carrier was completely immersed in the sample. The reaction was continued for 2 min, 5 min, 10 min, and 20 min. The infected carrier was added to a 5.0 mL PBS test tube, mixed, and shaken. The test bacteria were washed off and the live bacteria were cultured and counted. The experiment was repeated three times, and the antibacterial rate of different test samples was calculated.

[0036] The Gowing method was used to evaluate the effect of component A and component B on the antibacterial performance of Candida albicans after mixing. The formula is E0=X+[Y×(100-X) / 100], where E0 represents the theoretical antibacterial rate of the composition (A+B) against Candida albicans when the dosage is (P+Q), X represents the antibacterial rate of component A against Candida albicans when the dosage is P, and Y represents the antibacterial rate of component B against Candida albicans when the dosage is Q; E represents the actual antibacterial rate of the composition against Candida albicans.

[0037] When E-E0>10%, it is a synergistic effect; when E-E0<-10%, it is an antagonistic effect; when the E-E0 value is between ±10%, it is an additive effect.

[0038] Table 1 Antibacterial performance test results of matrine extract and lactobacillus compound on Candida albicans

[0039] Trial Groups E (actual inhibition rate) <![CDATA[E0(理论抑菌率)]]> [E-E0] Matrine: lactobacillus=0.001:0.5 52.10％ 50.26％ 1.84％ Matrine: lactobacillus=0.005:1 80.30％ 64.74％ 15.56％ Matrine: lactobacillus=0.01:2 99.90％ 66.03％ 33.87％ Matrine: lactobacillus=0.02:3 85.50％ 72.62％ 12.88％ Matrine: lactobacillus=0.04:6 65.20％ 71.43％ -6.23％ Matrine 0.001 9.80％ - - Matrine 0.005 12.20％ - - Matrine 0.01 12.80％ - - Matrine 0.02 13.20％ - - Matrine 0.04 11.10％ - - Lactobacillus 0.5 40.50％ - - Lactobacillus 1 52.60％ - - Lactobacillus 2 53.30％ - - Lactobacillus 3 59.50％ - - Lactobacillus 6 60.40％ - -

[0040] For example, first, 0.001 g of matrine and 1 g of lactobacillus were weighed, dissolved in deionized water and the volume was adjusted to 100 mL.

[0041] Matrine: lactobacillus = 0.005:1 means weighing 0.005g matrine, dissolving 1g lactobacillus in deionized water and adjusting the volume to 100mL; matrine 0.001 means weighing 0.001g matrine, dissolving it in deionized water and adjusting the volume to 100mL; lactobacillus 0.5 means weighing 0.5g lactobacillus, dissolving it in deionized water and adjusting the volume to 100mL.

[0042] The results in Table 1 show that when the mass ratio of matrine to lactobacillus is 0.005-0.02:1-3, the inhibition rate E-E0 on Candida albicans is greater than>10%, indicating that the two have a synergistic antibacterial effect within this range. Other mixing ratios in Table 1 have an additive effect. It is worth noting that when matrine: lactobacillus=0.01:2, the two mixed pairs have the best antibacterial effect on Candida albicans, with an inhibition rate of 99.9%. Therefore, the subsequent product development adopts matrine: lactobacillus=0.01:2 ratio.

[0043] Example 2

[0044] This example is the preparation of antibacterial non-menstrual pads based on sustained-release capsules.

[0045] The antibacterial non-menstrual panty liner based on sustained-release capsules is composed of a three-layer composite structure of a surface layer, a functional layer and a bottom layer.

[0046] The surface layer material is a silk protein modified non-woven fabric with a pore size of 80-120μm and a porosity of ≥35%. The functional layer is a cellulose-based 3D mesh scaffold with a porosity of ≥50%, which is loaded with sustained-release microcapsules. The bottom ...00g / m 2 / 24h DuPont TM 1073B breathable membrane.

[0047] Preparation of sustained-release microcapsules: 0.01% matrine and 2% lactobacillus were dissolved in glycerol-water (3:7) solvent and ultrasonically emulsified at 200W for 5 min to form a core drug emulsion; the emulsion was dropped into 2% sodium alginate solution and stirred at 500 rpm to form microdroplets, which were then transferred to 1.5% The solution solidified for 10 minutes to generate sodium alginate gel microspheres, which were then immersed in a 1.5% chitosan solution at pH 5.0 for electrostatic deposition coating for 15 minutes to form a double-layer structure with a wall thickness of 10-15 μm. The microspheres were then vacuum dried at 40°C for 4 hours to obtain dry microcapsules with a particle size of 150-200 μm.

[0048] Assembly of antibacterial non-menstrual pads based on sustained-release capsules: (1) Functional layer loaded with microcapsules: immerse the cellulose-based mesh scaffold in the microcapsule suspension (control density 50-80 particles / cm 2 ) and fixed by vacuum adsorption; (2) Three-layer composite: the surface layer and the functional layer are combined by hot pressing spot welding at 80℃ and 0.3MPa for 2s, and the functional layer and the bottom layer are bonded and cured at room temperature for 24h using medical-grade polyurethane glue; (3) Cutting and packaging: Cut according to standard size and seal the packaging.

[0049] Example 3

[0050] This example is an accelerated release test of sustained-release capsules in antibacterial non-menstrual panty liners based on sustained-release capsules.

[0051] To evaluate the drug release performance of the sustained-release microcapsule system loaded in the antibacterial non-menstrual pad based on sustained-release capsules in a simulated human body hot and humid environment, and verify its sustained-release efficiency and stability.

[0052] Environmental parameters: Constant temperature and humidity chamber (37±0.5℃, relative humidity 75±5%)

[0053] Test medium: simulated body fluid (pH 5.5 phosphate buffer containing 0.1% Tween 80 to simulate physiological mucus environment)

[0054] Sample processing: Take the functional layer material containing sustained-release capsule (area 5cm 2 ), placed in a dialysis bag (MWCO 12-14kDa), immersed in 100mL of medium, and shaken at a constant speed of 50rpm. Samples were taken and tested at 2h, 6h, and 12h, and three groups of samples were tested in parallel at each time point to calculate the release rate. The release rate calculation was based on the concentration of matrine and lactobacillus detected by high performance liquid chromatography (HPLC), with the total drug loading as the benchmark. The test results are shown in Table 2:

[0055] Table 2 Accelerated release results of sustained-release capsules in antibacterial non-menstrual pads

[0056] Time (h) Cumulative release rate (%) 2 18.5±2.1 6 63.2±3.4 12 89.7±2.8

[0057] The release rate reached 18.5% in the 0-2 hour period, presumably due to the rapid dissolution of the surface microcapsule coating, ensuring rapid drug onset. The release rate increased to 63.2% in the 2-6 hour period, likely due to the swelling and degradation of the sodium alginate-chitosan double-layer coating, combined with the porous structure of the cellulose-based scaffold, promoting medium penetration and achieving sustained drug release. The release rate reached 89.7% in the 6-12 hour period, slowing the release rate, suggesting that the double-layer coating effectively extended the release period and avoided sudden drug release. The cumulative release rate over 12 hours approached 90%, meeting the continuous drug supply requirements of long-lasting care products, with no significant hysteresis. This demonstrates that the microcapsule system exhibited excellent sustained-release properties in accelerated release testing. The combination of a rapid initial response and stable release later in the period meets the long-term antibacterial and anti-inflammatory needs of antibacterial non-menstrual pads under complex conditions such as humidity fluctuations.

[0058] Example 4

[0059] This embodiment is a test of the air permeability and moisture permeability of an antibacterial non-menstrual panty liner based on sustained-release capsules.

[0060] Comparison of conventional panty liners with the antibacterial non-menstrual panty liners based on sustained-release capsules of the present invention. The air permeability was tested using a YG461E digital air permeability meter in accordance with GB / T 5453-1997 "Determination of Air Permeability of Textile Fabrics." Parameters: Test area 20 cm 2 , pressure difference 100Pa, ambient temperature and humidity 25±2℃ / 65±5%RH.

[0061] Water vapor transmission rate (Vapor Permeability) was measured using a W3 / 060 water vapor transmission rate tester in accordance with GB / T 12704.2-2009, "Textiles - Test Method for Water Vapor Permeability - Part 2: Evaporation Method." Parameters: test cup diameter 60 mm, humidity gradient (90% RH → 10% RH), test duration 24 hours. The test results are shown in Table 3.

[0062] Table 3 Measurement results of air permeability and moisture permeability of different pads

[0063]

[0064] The results show that the bacteriostatic non-menstrual pad based on the slow-release capsule provided by the application has an air permeability and moisture permeation amount increased by 212% and 300% respectively compared with the conventional pad material, and the use comfort and sanitary safety are significantly improved.

[0065] The above description describes the basic principles, main features and advantages of the application. The above examples and descriptions are only used to describe the preferred embodiments of the application, and the application is not limited by the above examples. Various changes and improvements to the technical solutions of the application made by those skilled in the art without departing from the spirit and scope of the application shall fall within the scope of protection of the application.

Claims

1. An antibacterial composition, characterized in that The antibacterial composition consists of matrine and lactobacillus, and the antibacterial composition inhibits the growth of Candida albicans.

2. The antibacterial composition according to claim 1, characterized in that The mass ratio of matrine to lactobacillus is 0.005-0.02:1-3.

3. A sustained-release microcapsule, characterized in that: The antibacterial composition according to claim 1 or 2 is used as a core component, and a double-layer structure is formed by coating sodium alginate gel microspheres with chitosan.

4. The sustained-release microcapsule according to claim 3, characterized in that The sodium alginate gel microspheres are formed by dropping the core component emulsion into the sodium alginate solution and Solidified in solution.

5. The sustained-release microcapsule according to claim 3, characterized in that The chitosan coating is achieved by immersing the sodium alginate gel microspheres in a chitosan solution with a pH of 5.

0.

6. The sustained-release microcapsule according to claim 3, characterized in that The sustained-release microcapsules have a particle size of 150-200 μm and a wall thickness of 10-15 μm.

7. An antibacterial non-menstrual pad based on sustained-release capsules, characterized in that: include: The surface layer is made of silk protein modified non-woven fabric with a pore size of 80-120 μm and a porosity of ≥35%; A functional layer, composed of a cellulose-based 3D mesh scaffold, wherein the functional layer is loaded with the sustained-release microcapsule according to any one of claims 3 to 6; And the bottom layer.

8. The antibacterial non-menstrual pad according to claim 7, characterized in that: The loading density of the sustained-release microcapsules in the functional layer is 50-80 particles / cm 2 .

9. The method for preparing the antibacterial non-menstrual pad according to any one of claims 7 to 8, characterized in that: The following steps are involved: S1, immersing the cellulose-based mesh scaffold in a sustained-release microcapsule suspension and fixing the microcapsules by vacuum adsorption; S2. The surface layer and the functional layer are bonded by hot pressing spot welding at 80°C and 0.3 MPa for 2 seconds, and the functional layer and the bottom layer are bonded by medical-grade polyurethane adhesive at room temperature and cured for 24 hours; S3. Cut and seal the packaging.

10. The antibacterial non-menstrual pad prepared by the preparation method of claim 9, characterized in that: The antibacterial non-menstrual pad has an antibacterial effect, and the antibacterial effect is the inhibition of Candida albicans.

Images